Capricor Therapeutics

Contributing Author

Recent Articles by Capricor Therapeutics

May-04	Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 CAPR +8.38% GlobeNewswire
Apr-22	Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting CAPR GlobeNewswire
Mar-12	Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update CAPR -8.74% CAPR GlobeNewswire
Mar-12	Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy CAPR GlobeNewswire
Mar-10	Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA CAPR +9.04% GlobeNewswire
Mar-10	Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA CAPR +9.04% GlobeNewswire
Mar-09	Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 CAPR +9.78% GlobeNewswire
Feb-24	Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference CAPR GlobeNewswire
Jan-20	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data CAPR GlobeNewswire
Dec-16	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy CAPR GlobeNewswire
Dec-05	Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock CAPR +5.87% GlobeNewswire
Dec-04	Capricor Therapeutics Announces Proposed Public Offering of Common Stock CAPR -15.22% GlobeNewswire
Dec-03	Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy CAPR +371.07% GlobeNewswire
Nov-24	Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025 CAPR -19.30% GlobeNewswire
Nov-10	Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update CAPR +11.51% CAPR -6.24% GlobeNewswire
Nov-03	Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel CAPR -6.76% GlobeNewswire
Oct-31	Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 CAPR GlobeNewswire
Sep-25	Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting CAPR +5.33% GlobeNewswire
Sep-09	Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel CAPR GlobeNewswire
Aug-18	Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine CAPR GlobeNewswire
Aug-11	Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update CAPR -13.84% GlobeNewswire
Aug-08	Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA CAPR +12.39% GlobeNewswire
Aug-06	Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 CAPR GlobeNewswire
Jul-28	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jul-11	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy CAPR -32.98% GlobeNewswire
Jun-24	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy CAPR +20.44% GlobeNewswire
Jun-20	Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy CAPR -30.82% GlobeNewswire
Jun-17	Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program CAPR GlobeNewswire
Jun-11	Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program CAPR -5.40% GlobeNewswire
May-13	Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update CAPR +5.07% CAPR GlobeNewswire
May-13	Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer CAPR GlobeNewswire
May-06	Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 CAPR -29.13% GlobeNewswire
May-05	Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy CAPR -13.15% GlobeNewswire

Capricor Therapeutics

Recent Articles by Capricor Therapeutics

Upgrade your Finviz experience